Graft-versus-host Disease Prevention

Human leukocyte antigen (HLA) matching lowers the immunologic mismatch between donor and recipient, reducing the likelihood that donor-derived T cells will identify recipient tissues as foreign. It is therefore a donor-selection measure rather than a post-transplant drug treatment. In prevention planning, matching works alongside graft processing and immunosuppression to reduce GvHD risk.

T-cell reduction or depletion changes the cellular composition of the graft before infusion. Because donor-derived T cells drive recognition, activation, and inflammatory signaling against recipient tissues, reducing their number can limit that sequence. The challenge is balance: prevention should decrease harmful immune attack while preserving graft-versus-leukemia activity and supporting engraftment and immune recovery.

Drug prophylaxis commonly combines a calcineurin inhibitor with methotrexate or uses post-transplant cyclophosphamide. These preventive regimens complement donor selection and graft processing rather than replacing them. Their use is important because protection from GvHD must be pursued alongside engraftment, immune recovery, and retention of beneficial graft-versus-leukemia activity.

Prevention is not intended to remove every donor immune effect. Donor-derived T cells can contribute to beneficial graft-versus-leukemia activity, so reducing harmful recognition of recipient tissues must be balanced against preserving that activity. This balance explains why clinicians combine donor selection, graft processing, and prophylactic drugs rather than relying on a single intervention.

A prevention plan begins with donor selection, including HLA matching, then considers graft processing to reduce or deplete T cells and establishes prophylactic immunosuppression. Regimens may pair a calcineurin inhibitor with methotrexate or use post-transplant cyclophosphamide. Together, these decisions address risk through coordinated cellular and drug-based measures surrounding transplantation.

Evaluation considers more than reduced GvHD risk. An effective strategy should also support engraftment and immune recovery while preserving beneficial graft-versus-leukemia activity. Protection of the skin, liver, and gastrointestinal tract is another relevant outcome. These endpoints reflect the central clinical tradeoff between controlling donor immune attack and retaining useful transplant effects.